PMID- 30360963
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20190916
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 20
IP  - 11
DP  - 2018 Nov
TI  - Empowering dendritic cell cancer vaccination: the role of combinatorial 
      strategies.
PG  - 1309-1323
LID - S1465-3249(18)30616-9 [pii]
LID - 10.1016/j.jcyt.2018.09.007 [doi]
AB  - Dendritic cells (DCs) are bone marrow-derived immune cells that play a crucial 
      role in inducing the adaptive immunity and supporting the innate immune response 
      independently from T cells. In the last decade, DCs have become a hopeful 
      instrument for cancer vaccines that aims at re-educating the immune system, 
      leading to a potent anti-cancer immune response able to overcome the 
      immunosuppressive tumor microenvironment (TME). Although several studies have 
      indicated that DC-based vaccines are feasible and safe, the clinical advantages 
      of DC vaccination as monotherapy for most of the neoplasms remain a distant 
      target. Recently, many reports and clinical trials have widely used innovative 
      combinatorial therapeutic strategies to normalize the immune function in the TME 
      and synergistically enhance DC function. This review will describe the most 
      relevant and updated evidence of the anti-cancer combinatorial approaches to 
      boost the clinical potency of DC-based vaccines.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Galati, Domenico
AU  - Galati D
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology 
      and Innovative Therapies, Istituto Nazionale Tumori - IRCCS - Fondazione 'G. 
      Pascale', Napoli, Italy. Electronic address: d.galati@istitutotumori.na.it.
FAU - Zanotta, Serena
AU  - Zanotta S
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology 
      and Innovative Therapies, Istituto Nazionale Tumori - IRCCS - Fondazione 'G. 
      Pascale', Napoli, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181022
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adaptive Immunity
MH  - Animals
MH  - CTLA-4 Antigen/immunology
MH  - Cancer Vaccines/immunology/*pharmacology
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunity, Innate
MH  - Immunosuppressive Agents/pharmacology
MH  - Immunotherapy/methods
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/immunology
MH  - Tumor Microenvironment/*immunology
OTO - NOTNLM
OT  - cancer vaccines
OT  - combination strategies
OT  - dendritic cell vaccines
OT  - dendritic cells
OT  - immunotherapy
EDAT- 2018/10/27 06:00
MHDA- 2019/09/17 06:00
CRDT- 2018/10/27 06:00
PHST- 2018/06/26 00:00 [received]
PHST- 2018/09/18 00:00 [revised]
PHST- 2018/09/19 00:00 [accepted]
PHST- 2018/10/27 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
PHST- 2018/10/27 06:00 [entrez]
AID - S1465-3249(18)30616-9 [pii]
AID - 10.1016/j.jcyt.2018.09.007 [doi]
PST - ppublish
SO  - Cytotherapy. 2018 Nov;20(11):1309-1323. doi: 10.1016/j.jcyt.2018.09.007. Epub 
      2018 Oct 22.